ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, CRISPR-Cas9 has been employed to uncover resistance mechanisms in BCR-ABL-driven CML, such as mutations in downstream effectors like STAT5, guiding the design of next-generation TKIs [184].